Vernakalant Versus Ibutilide In Recent-Onset Atrial Fibrillation

Atrial Fibrillation Clinical Trial

Official title:

Vernakalant Versus Ibutilide In Recent-Onset Atrial Fibrillation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01447862
• Other study ID #: Verna-Ibu-AF
• Status: Completed
• Phase: Phase 4
• First received: October 5, 2011
• Last updated: May 12, 2015
• Start date: October 2011
• Est. completion date: May 2015

Study information

• Verified date: May 2015
• Source: Medical University of Vienna
• Contact: n/a
• Is FDA regulated: No
• Health authority: Austria : Federal Ministry for Labour, Health, and Social Affairs
• Study type: Interventional

Clinical Trial Summary

Atrial fibrillation is the most common cardiac arrhythmia and is expected to affect about 30 million North Americans and Europeans by 2050. Atrial fibrillation is associated with increased cardiovascular morbidity and mortality, with stroke being an especially important and potentially devastating complication. Many studies have investigated the efficacy of different drugs in converting atrial fibrillation to sinus rhythm. There are numerous randomized controlled trials that have tested the efficacy of agents against placebo and some trials that directly compared the efficacy of two or more different drugs. The class III antiarrhythmic drug Ibutilde is approved for the acute termination of atrial fibrillation and atrial flutter of recent onset and has been shown to be superior to sotalol and equivalent to flecainide in this indication. Recently, the relatively atrial selective antiarrhythmic agent vernakalant has been approved by the European Commission for the rapid conversion of recent onset AF to sinus rhythm in adults. The investigators hypothesize that the period of time needed for cardioversion to sinus rhythm and the efficacy of cardioversion within 90 minutes is different between vernakalant and ibutilide in patients with recent-onset atrial fibrillation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 101
• Est. completion date: May 2015
• Est. primary completion date: May 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• Symptoms of atrial fibrillation since no longer than 48 hours

• Age 18 - 90 years

Exclusion Criteria:

• Need for immediate electrical cardioversion due to hemodynamic instability (hypotension: systolic blood pressure < 100 mmHg, dyspnea, loss of consciousness, unstable angina)

• Moderate to severe heart failure (NYHA III/IV) and patients with previously documented left ventricular ejection fraction (LVEF) = 35%

• History or signs of acute coronary syndromes (acute myocardial infarction, unstable angina) within the last 30 days

• Resting ventricular rate < 80 beats per minute without pace maker back-up

• QT interval of > 440 milliseconds

• Wolff-Parkinson-White (WPW) syndrome

• History of Torsade de pointes arrhythmias or other polymorphic ventricular tachycardias

• Signs of thyreotoxicosis

• Sick Sinus Syndrome or atrioventricular block greater than first degree

• Severe valvular heart disease, clinically meaningful hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy, or constrictive pericarditis

• Serious disorders of the hepatic, renal (Creatinine > 2.5mg/dl), pulmonary, gastrointestinal, hematologic or central nervous system and serious psychiatric disorders

• Abnormal serum electrolytes despite adequate therapy (especially potassium <3.5 mmol/l or > 5.5 mmol/l)

• Intravenous use of other Class I or III antiarrythmic drugs within 4 hours of study drug application

• Pregnancy (a ß-HCG test will be performed in all female subjects apart from women > 50 years and with amenorrhea for at least 12 month (absence of other causes of amenorrhoea)

• Known hypersensitivity to study medication

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Atrial Fibrillation

Intervention

Drug:
• Brinavess (Vernakalant)
3mg/kg Brinavess (Vernakalant) in 100ml normal saline over 10min. If atrial fibrillation continues after another 15 minutes of observation, patients will receive a second infusion of 2mg/kg Brinavess (Vernakalant) over 10 minutes
• Corvert (Ibutilide)
Patients will be given 1mg of Corvert (Ibutilide) in 100ml normal saline intravenously over 10min. If atrial fibrillation continues after another 10 minutes of observation, patients will receive a second infusion of 1mg ibutilide over 10min.

Locations

Country	Name	City	State
Austria	Medical University of Vienna, Department of Emergency Medicine	Vienna

Sponsors (1)

Lead Sponsor	Collaborator
Medical University of Vienna

Country where clinical trial is conducted

Austria, 

References & Publications (3)

Camm AJ, Capucci A, Hohnloser SH, Torp-Pedersen C, Van Gelder IC, Mangal B, Beatch G; AVRO Investigators. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol. 2011 Jan 18;57(3):313-21. doi: 10.1016/j.jacc.2010.07.046. — View Citation

Domanovits H, Schillinger M, Thoennissen J, Nikfardjam M, Janata K, Brunner M, Laggner AN. Termination of recent-onset atrial fibrillation/flutter in the emergency department: a sequential approach with intravenous ibutilide and external electrical cardioversion. Resuscitation. 2000 Aug 1;45(3):181-7. — View Citation

Stiell IG, Dickinson G, Butterfield NN, Clement CM, Perry JJ, Vaillancourt C, Calder LA. Vernakalant hydrochloride: A novel atrial-selective agent for the cardioversion of recent-onset atrial fibrillation in the emergency department. Acad Emerg Med. 2010 Nov;17(11):1175-82. doi: 10.1111/j.1553-2712.2010.00915.x. Erratum in: Acad Emerg Med. 2011 Feb;18(2):224. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time in minutes until conversion to sinus rhythm (measured from the start of the first study drug administration)		90 minutes	No
Secondary	Conversion rate to sinus rhythm within 90 minutes (measured from the start of the first study drug administration)		90 minutes	No